349 Early safety and efficacy of a phase 1/2 open-label, multi-center trial of SNS-301 added to pembrolizumab in patients with advanced squamous cell carcinoma of the head and neck (SCCHN)

• William Smith,
• Jean Campbell,
• Timothy Panella,
• Dong Shin,
• Marie-Louise Fjaellskog,
• John Celebi,
• Alice Drumheller,
• Robert Pierce,
• Michael Guarino

Affiliations

William Smith

2New Oreleans Clincal Research, Knoxville, TN, USA

Jean Campbell

Aff164 OncoSec Medical Inc. San Diego CA USA

Timothy Panella

3University of Tennessee, Knoxville, TN, USA

Dong Shin

4Emory University, Atlanta, GA, USA

Marie-Louise Fjaellskog

5Sensei Biotherapeutics, Boston, MA, USA

John Celebi

5Sensei Biotherapeutics, Boston, MA, USA

Alice Drumheller

5Sensei Biotherapeutics, Boston, MA, USA

Robert Pierce

5Sensei Biotherapeutics, Boston, MA, USA

Michael Guarino

6Christiana Hospital, Newark, DE, USA